The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...